Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUNLUN ENERGY
00135
5
CNOOC
00883
CN Stock MarketDetailed Quotes
Yunnan Botanee Bio-Technology Group (300957)
- 33.91
- -0.10-0.29%
Market Closed Jun 16 15:00 CST
14.36BMarket Cap26.43P/E (TTM)
34.24High33.05Low72.04KlotVolume33.91Open34.01Prev Close241.15MTurnover1.70%Turnover Ratio28.40P/E (Static)423.60MShares51.1552wk High2.35P/B14.36BFloat Cap31.8852wk Low40.81Limit Up423.60MShs Float286.11Historical High27.21Limit Down3.50%Range %31.88Historical Low0.65Dividend TTM33.48Avg Price31.61KlotAsk1.92%Div Yield TTM100Lot Size37.60KlotBid
Yunnan Botanee Bio-Technology Group (300957) News
Ten Years of Nanbo, Advancing Toward Sustainability | Biotime Group Writes a New Chapter for Oriental Beauty with Original Innovation and Sustainable Value
On June 11, the 10th China–South Asia Expo (hereinafter referred to as "CSAE") officially opened at the Dianchi International Convention and Exhibition Center in Kunming. Under the theme "Unity and Collaboration for Shared Development," this year’s expo reached record highs in both scale and international participation, attracting over 60 countries and regions and approximately 560 enterprises from South Asia. Led by Betaine Group, numerous high-quality companies have set up exhibits in Hall 10—dedicated to medical care and wellness—showcasing how technology leverages Yunnan’s resource advantages to drive the group’s industrial competitiveness. As China’s leading efficacy-focused skincare enterprise, Betaine Group is presenting its portfolio of brands, including Winona, Winona Baby, Aekemarn, Beffteen, and Chu
Guosen Securities: The 618 Shopping Festival Reflects a New Shift in AI and Distribution Channels; High-Quality Market Leaders Demonstrate Resilience
Maintain an "outperform" rating for the commercial and retail sector.
Betaine (300957): Operational Improvement and Profitability Recovery
The company released its 2025 annual report and Q1 2026 results, showing marginal improvement in Q4 2025 and Q1 2026. In 2025, the company reported revenue of RMB 5.359 billion, down 6.58% year-over-year, and net profit attributable to shareholders of RMB 506 million.
Domestic cosmetic skincare enters its second half, and Betty Biotech plays three key cards: #R&DOriginalInnovation #GlobalExpansion #SustainableDevelopment #BeautyBeginsWithin
#R&D Originality#Going Global#Sustainable Development#Beauty Originates from Within
Kaiyuan Securities Retail & Consumer Services 2026 Strategy: Divergent Consumer Recovery, Premium Segment Leading, Services Embracing Innovation
Notably, high-end consumption is showing a faster recovery trend, and the comprehensive integration of AI into consumer scenarios is expected to reshape business models and enhance corporate operational efficiency.
The release of the medical insurance individual account whitelist may signal a decline in pharmacy-related benefits for 'medical beauty masks'.
On May 19, the Office of the National Healthcare Security Administration and the Office of the Ministry of Finance issued the 'Notice on Further Strengthening the Use of Individual Accounts in the Basic Medical Insurance for Employees at Designated Retail Pharmacies...'
CICC: The time is ripe for consumption to flow back home and for attracting overseas spending; the "Four Confidences" are driving a broad-based recovery in the sector.
At this juncture, there should no longer be any preoccupation with the marginal impact of real estate prices or capital market performance on consumption. Strengthening the 'Four Confidences' will help restore consumer confidence and drive an overall recovery in the consumer sector.
BeiTaiNi (300957) 2025 Annual Report and Q1 Commentary: Upward Business Trend Continues, Share Repurchase Boosts Confidence
The company released its 2025 annual report and Q1 report. In 2025, the company achieved operating revenue of 5.36 billion yuan, representing a year-on-year decline of 6.6%, while net profit attributable to shareholders reached 500 million yuan, remaining essentially flat year-on-year. Non-recurring net profit showed signs of recovery.
Beitai Ni (300957): Outstanding performance in online channels and new brands significantly restores profitability
The company released its 2025 annual report and Q1 2026 earnings report: In 2025, the company achieved operating revenue of 5.359 billion yuan, a year-on-year decrease of 6.58%; net profit attributable to shareholders of 506 million yuan, a year-on-year increase of 0.53%; after deducting non-recurring items
Huayuan Securities: The cosmetics sector demonstrated steady performance in Q1 2026, with high-quality domestic brands showcasing strong competitiveness.
In 2025, the year-on-year growth rate of retail sales of cosmetics products by large-scale enterprises in China reached 5.1%, surpassing the overall growth rate of 3.7% for total retail sales of consumer goods in China, with overall performance remaining relatively stable.
Betaini (300957.SZ) has not yet implemented a share repurchase.
Gelonghui reported on May 7 that Beitan Ni (300957.SZ) announced it had not yet implemented a share repurchase as of April 30, 2026.
Commentary on Botanee (300957) 2025 Annual Report & 2026 Q1 Report: Significant Growth in Revenue and Profit for Q1 2026, Clear Signs of Operational Improvement
Key investment highlights: The company announced its 2025 annual report and Q1 2026 performance. In 2025, it achieved revenue of 5.359 billion yuan (-6.58% year-on-year, hereinafter the same), net profit attributable to shareholders of 506 million yuan (+0.53%), and non-recurring
Beitainei (300957): Revenue and profitability recovery exceeds expectations; focus on the company's recovery milestones and growth potential.
The company disclosed its financial results for the year 2025 and the first quarter of 2026, surpassing market expectations. In 2025, revenue reached 5.359 billion yuan, a decrease of 6.58% year-on-year, while net profit attributable to shareholders was 506 million yuan, an increase of 0.53% year-on-year. Non-recurring net profit attributable to shareholders amounted to 356 million yuan.
Beitai Ni (300957): Initial effects of cost control measures become visible; Q1 2026 revenue and profit performance exceed expectations.
Beitainei released its 2025 annual report. The company achieved revenue of 5.36 billion yuan in 2025, representing a year-on-year decrease of 6.6%. Net profit attributable to shareholders reached 510 million yuan, marking a year-on-year increase of 0.5%, while net profit excluding non-recurring items stood at 360 million yuan, showing a year-on-year
Jefferies Adjusts Yunnan Botanee Bio-Technology's Price Target to 40 Yuan From 42 Yuan, Keeps at Hold
BeiTaeni (300957) 2025 Annual Report and 2026 Q1 Earnings Commentary: Strong Performance in Q1 Driven by Multi-Brand Synergy
Event: The company released its 2025 annual report and the first-quarter report for 2026. Commentary: First-quarter performance was outstanding, with cost optimization driving earnings growth. In 2025, the company achieved revenue of 5.359 billion yuan, representing a year-on-year decrease of 6.58%;
Beitaini (300957): Significant results from strategic adjustments, with continuous improvement in profitability
The company's strategic adjustments in 2025 have yielded significant results, with full-year profitability stabilizing and rebounding. Performance in Q4 2025 and Q1 2026 shows an accelerating recovery trend. In 2025, revenue from the core brand Winona experienced a slight decline, while emerging brands achieved rapid growth, demonstrating strong multi-brand synergy.
Comment on Beiteini (300957): Brand Portfolio Renewal and Synergistic Advancement Enters a New Phase of High-Quality Growth
The company released its annual report for the 25th year and the first-quarter report for the 26th year, with performance exceeding expectations. Revenue in the 25th year amounted to 5.359 billion yuan, representing a year-on-year decrease of 6.58%; net profit attributable to shareholders was 506 million yuan, marking a year-on-year increase of 0.53%; non-recurring net profit...
Beitainei (300957): Overall performance stabilizes and rebounds, multi-brand portfolio contributes new growth
The company's performance has stabilized and shown signs of recovery. In 2025, the company achieved revenue of 5.359 billion/yoy-6.58%, net profit attributable to shareholders of 506 million/yoy+0.53%, and non-recurring net profit attributable to shareholders of 356 million/
Beitainei (300957): Q1 revenue growth accelerated and profitability improved year-over-year; initial signs of operational improvement have emerged.
The company’s FY25 performance met market expectations, while its 1Q26 results slightly exceeded our expectations. The company reported FY25 and 1Q26 financial results: FY25 revenue was RMB 5.36 billion, a year-on-year decrease of 6.6%; net profit was RMB 510 million, a year-on-year increase of 0.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On Tuesday, Trump stated that the United States and Iran had successfully signed a memorandum of understanding online, and that their negoti
牛牛課堂
Jun 15 14:46
美伊和平曙光初現！全球市場「拆彈式狂歡」：誰在帶頭衝鋒，升势還能跑多遠？
Queen女王学期权
Jun 15 16:22
After the U.S.-Iran memorandum of understanding, crude oil dropped 5%, and my first instinct was to check calls on airline stocks